Vivos Therapeutics files prospectus supplement for up to $5.83M ATM offering

Vivos Therapeutics, Inc.

Company may sell up to $5,830,572 of common stock through H.C. Wainwright as sales agent.
No shares had been sold under prior ATM agreement as of September 12, 2025.
Shelf registration statement S-3 (333-284834) declared effective by SEC on September 10, 2025.
Common stock par value $0.0001 per share; proceeds for general corporate purposes.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.